<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144447">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687985</url>
  </required_header>
  <id_info>
    <org_study_id>BLI801-202</org_study_id>
    <nct_id>NCT01687985</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults</brief_title>
  <official_title>A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to evaluate the safety and efficacy of multiple BLI801 doses in constipated
      adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Treatment Success</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>percent of patients experiencing a response in 3 out of 4 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum chemistry</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>BLI801 laxative - low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLI801 laxative - oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLI801 laxative - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLI801 laxative - oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI801 laxative - low dose</intervention_name>
    <description>BLI801 laxative - oral solution</description>
    <arm_group_label>BLI801 laxative - low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI801 laxative - high dose</intervention_name>
    <description>BLI801 laxative - oral solution</description>
    <arm_group_label>BLI801 laxative - high dose</arm_group_label>
    <other_name>BLI801</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female subjects at least 18 years of age

        Constipated, defined  by ROME definition:

        Otherwise in good health, as determined by physical exam and medical history

        Exclusion Criteria:

        Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention,
        bowel perforation, toxic colitis, toxic megacolon

        Subjects taking laxatives  or prokinetic agents that refuse to discontinue these
        treatments

        Subjects who are allergic to any BLI801 component

        Subjects currently taking narcotic analgesics or other medications known to cause
        constipation

        Subjects who, in the opinion of the Investigator, should not be included in the study for
        any reason, including inability to follow study procedures

        Subjects who have participated in an investigational clinical, surgical, drug, or device
        study within the past 30 days

        Subjects with an active history of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinsearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastroenterology</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>September 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Laxatives</mesh_term>
    <mesh_term>Cathartics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
